Rani Therapeutics Holdings, Inc. Class A Common Stock (RANI)
Rani Therapeutics Holdings, Inc. Class A (RANI) is a biopharmaceutical company focused on developing oral biologic delivery platforms. Their flagship technology involves using an ingestible, self-orienting robotic pill to deliver biologic drugs orally, aiming to replace injections for various conditions. The company is committed to advancing innovative drug delivery solutions to improve patient experiences and treatment outcomes.
Company News
~ New RT-114 obesity program combines ProGen’s FC Fusion protein conjugated GLP-1/GLP-2 dual agonist, PG-102, with the RaniPill® capsule designed to provide a differentiated oral delivery mechanism with bioavailability comparable to subcutaneous injection ~
U.S. stock futures were higher this morning, with the Dow futures gaining over 50 points on Thursday. Shares of Equifax Inc. (NYSE: EFX) fell sharply in today’s pre-market trading after the company reported worse-than-expected first-quarter sales results and issued adjusted guidance below estimates. Equifax posted quarterly sales of $1.389 bil...
Rani Therapeutics Holdings, Inc. (RANI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
A game-changing pill from Rani Therapeutics may offer an easier alternative to fight debilitating diseases.